| NCT03072771 | Washington University School of Medicine|Amgen | Diffuse Large B Cell Lymphoma | 2017-08-01 | PHASE1 |
| NCT03147612 | M.D. Anderson Cancer Center | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia With BCR-ABL1|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia | 2018-02-08 | PHASE2 |
| NCT04044560 | University of British Columbia|Amgen | B-cell Adult Acute Lymphoblastic Leukemia|Stem Cell Leukemia|Minimal Residual Disease | 2020-09-08 | PHASE2 |
| NCT02101853 | National Cancer Institute (NCI) | Recurrent B Acute Lymphoblastic Leukemia | 2014-12-17 | PHASE3 |
| NCT02187354 | Amgen | Relapsed+Refractory B-Precursor Acute Lymphoblastic Leukemia | | |
| NCT06387121 | Institute of Hematology & Blood Diseases Hospital, China | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2024-04-02 | PHASE2 |
| NCT02143414 | National Cancer Institute (NCI) | Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Recurrent Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia | 2015-06-30 | PHASE2 |
| NCT03109093 | Goethe University | ALL, Recurrent, Adult | 2017-03-15 | PHASE2 |
| NCT02412306 | Amgen|Amgen Astellas Biopharma K.K. | Relapsed Refractory B Precursor Acute Lymphoblastic Leukemia | 2015-06-04 | PHASE1|PHASE2 |
| NCT02568553 | National Cancer Institute (NCI) | Recurrent Burkitt Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Grade 3a Follicular Lymphoma|Recurrent Grade 3b Follicular Lymphoma|Recurrent Gray-Zone Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mediastinal Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Burkitt Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Grade 1 Follicular Lymphoma|Refractory Grade 2 Follicular Lymphoma|Refractory Grade 3 Follicular Lymphoma|Refractory Grade 3a Follicular Lymphoma|Refractory Gray-Zone Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Marginal Zone Lymphoma|Refractory Mediastinal Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Small Lymphocytic Lymphoma | 2016-11-15 | PHASE1 |
| NCT07294677 | University of Chicago | Leukemia|Lymphoma | 2026-03-17 | PHASE1|PHASE2 |
| NCT04329325 | Memorial Sloan Kettering Cancer Center|Amgen | Acute Lymphoblastic Leukemia|Philadelphia Chromosome-Positive | 2020-03-30 | PHASE2 |
| NCT06287229 | M.D. Anderson Cancer Center | Relapsed+Refractory|B-cell Acute Lymphocytic Leukemia | 2024-07-11 | PHASE1|PHASE2 |
| NCT05827549 | Ho Joon Im|Samsung Medical Center|Seoul National University Hospital|Severance Hospital|Chonnam National University Hospital|Pusan National University Yangsan Hospital|Seoul St. Mary´s Hospital | Acute Lymphoid Leukemia | 2024-04-04 | PHASE2 |
| NCT07133997 | City of Hope Medical Center|National Cancer Institute (NCI) | Recurrent B Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia | 2026-06-01 | PHASE1 |
| NCT01471782 | Amgen Research (Munich) GmbH | Acute Lymphoblastic Leukemia | 2012-01 | PHASE1|PHASE2 |
| NCT06649006 | Amgen | B-precursor Acute Lymphoblastic Leukemia | 2025-01-08 | PHASE1 |
| NCT06554626 | First Affiliated Hospital of Zhejiang University | Precursor B-Cell Lymphoblastic Leukemia | 2024-08-15 | PHASE2 |
| NCT06250959 | Chen Suning | ALL, Adult|Philadelphia-Negative ALL | 2024-02-05 | PHASE2 |
| NCT06684184 | Zhongming Qiu | Myasthaenia Gravis | 2024-11-30 | PHASE2|PHASE3 |
| NCT06607419 | Shanghai Jiao Tong University School of Medicine|Fujian Maternity and Child Health Hospital|Zhangzhou Affiliated Hospital of Fujian Medical University|Guizhou Provincial People´s Hospital|The First Affiliated Hospital of Xiamen University|Dalian Women and Children´s Medical Center|The Third Xiangya Hospital of Central South University|Hunan Provincial People´s Hospital|Ningbo Women & Children´s Hospital|Anhui Provincial Children´s Hospital|Jiangxi Province Children´s Hospital|Yuying Children´s Hospital of Wenzhou Medical University | B-Cell Lymphoblastic Leukemia | 2024-05-21 | PHASE2|PHASE3 |
| NCT06504186 | Institute of Hematology & Blood Diseases Hospital, China | B-ALL | 2024-07 | NA |
| NCT03340766 | Amgen|Merck Sharp & Dohme LLC | Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) | 2018-03-16 | PHASE1 |
| NCT07283640 | M.D. Anderson Cancer Center|Amgen|Syndax Pharmaceuticals | Blinatumomab|Revumenib|Lymphoblastic Leukemia|KMT2A-rearranged | 2026-05-18 | PHASE1 |
| NCT03298412 | Amgen | High-risk Diffuse Large B-cell Lymphoma | 2018-05-23 | PHASE2 |
| NCT06339775 | Suping ZHANG | Acute B-cell Lymphoblastic Leukemia | 2023-09-01 | PHASE4 |
| NCT06763302 | The Children´s Hospital of Zhejiang University School of Medicine | B Cell Precursor Acute Lymphoblastic Leukemia|Pediatric|Minimal Residual Disease|Next Generation Sequencing (NGS) | 2025-01-01 | NA |
| NCT05837689 | Xiaojun Xu | Acute Lymphoblastic Leukemia, Pediatric | 2023-04 | |
| NCT03914625 | National Cancer Institute (NCI) | B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma|Down Syndrome | 2019-07-03 | PHASE3 |
| NCT04554485 | Institute of Hematology and Blood Transfusion, Czech Republic|CZECRIN - Czech Clinical Research Infrastructure Network | Lymphoblastic Leukemia, Acute, Adult|Ph Negative ALL|Newly Diagnosed | 2019-05-09 | PHASE2 |
| NCT04524455 | Amgen | Acute Lymphoblastic Leukemia | 2020-10-02 | PHASE1 |
| NCT07454226 | Institute of Hematology & Blood Diseases Hospital, China | Ph-Like|Acute Lymphoblastic Leukemia | 2026-04-30 | NA |
| NCT06220487 | Nanfang Hospital, Southern Medical University | Acute Lymphoblastic Leukemia|Philadelphia Chromosome|Philadelphia-Positive ALL|Adult ALL|IKZF1 Gene Mutation | 2024-02-01 | PHASE2 |
| NCT02458014 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Adult Acute Lymphoblastic Leukemia in Complete Remission|B Acute Lymphoblastic Leukemia|Minimal Residual Disease|Philadelphia Chromosome Positive | 2015-09-14 | PHASE2 |
| NCT04521231 | Amgen|BeOne Medicines | B Cell Precursor Acute Lymphoblastic Leukemia | 2021-01-04 | PHASE1|PHASE2 |
| NCT06507514 | The First Affiliated Hospital of Soochow University | B-cell Acute Lymphoblastic Leukemia | 2024-04-01 | PHASE1 |
| NCT01741792 | Amgen Research (Munich) GmbH | Diffuse Large B-cell Lymphoma | 2012-07 | PHASE2 |
| NCT06533748 | St. Jude Children´s Research Hospital|Pfizer|Amgen | Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma | 2025-01-23 | PHASE2 |
| NCT03595917 | Marlise Luskin, MD|Novartis | B-cell Acute Lymphoblastic Leukemia|Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis|Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph&addition; ALL | 2018-07-24 | PHASE1 |
| NCT03518112 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Philadelphia Chromosome Negative|Recurrent B Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia | 2018-04-18 | PHASE2 |
| NCT04994717 | Amgen | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | 2021-11-02 | PHASE3 |
| NCT06111625 | Sichuan University | Leukemia, Lymphoid | 2023-09-10 | PHASE2 |
| NCT03823365 | A.O. Ospedale Papa Giovanni XXIII | Indolent Non-Hodgkin Lymphomas+Chronic Lymphocytic Leukemia | 2018-12-17 | PHASE1 |
| NCT06063317 | Imugene Limited | Solid Tumor, Adult | 2023-10-02 | PHASE1 |
| NCT05182385 | Goethe University|University Hospital Schleswig-Holstein | ALL, Recurrent, Adult | 2021-12-15 | PHASE1|PHASE2 |
| NCT07570173 | Merck Sharp & Dohme LLC | B-cell Acute Lymphoblastic Leukemia | 2026-05-08 | PHASE2|PHASE3 |
| NCT02961881 | Amgen | Non-Hodgkin´s Lymphoma | 2017-09-18 | PHASE1 |
| NCT07192237 | M.D. Anderson Cancer Center|Amgen | Phase 2 Study|Blinatumomab|Acute Lymphoblastic Leukemia | 2026-09-27 | PHASE2 |
| NCT07493161 | Institute of Hematology & Blood Diseases Hospital, China | Ph&addition; ALL | 2026-04-01 | NA |
| NCT07052370 | St. Jude Children´s Research Hospital | Hematologic Malignancy | 2025-09-25 | PHASE1 |
| NCT03117751 | St. Jude Children´s Research Hospital|Incyte Corporation|Amgen|Servier | Acute Lymphoblastic Leukemia|Acute Lymphoblastic Lymphoma | 2017-03-29 | PHASE2|PHASE3 |
| NCT04872790 | OHSU Knight Cancer Institute|AbbVie|Oregon Health and Science University | B Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Mixed Phenotype Acute Leukemia|Recurrent B Acute Lymphoblastic Leukemia|Recurrent Mixed Phenotype Acute Leukemia | 2022-09-02 | PHASE1 |
| NCT02744768 | Gruppo Italiano Malattie EMatologiche dell´Adulto | Acute Lymphoblastic Leukemia | 2017-05-31 | PHASE2 |
| NCT07223190 | Amgen | Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia | 2026-06-11 | PHASE3 |
| NCT07564453 | The First Affiliated Hospital of Soochow University | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | 2025-04-01 | PHASE2 |
| NCT03541083 | Stichting Hemato-Oncologie voor Volwassenen Nederland | ALL, Adult | 2018-06-04 | PHASE2 |
| NCT07313852 | Memorial Sloan Kettering Cancer Center|Amgen|Pfizer | B-cell Acute Lymphoblastic Leukemia|B-Cell Acute Lymphoblastic Leukemia, Adult|B-ALL | 2026-06 | PHASE1|PHASE2 |
| NCT03643276 | Martin Schrappe|Deutsche Krebshilfe e.V., Bonn (Germany) | Acute Lymphoblastic Leukemia, Pediatric | 2018-07-15 | PHASE3 |
| NCT06054113 | Amgen | B Precursor Acute Lymphoblastic Leukemia|Relapsed+Refractory B Precursor Acute Lymphoblastic Leukemia | 2024-07-23 | PHASE2 |
| NCT03849651 | St. Jude Children´s Research Hospital | Acute Lymphoblastic Leukemia (ALL)|Acute Myeloid Leukemia (AML)|Myelodysplastic Syndromes (MDS)|NK-Cell Leukemia|Hodgkin Lymphoma|Non Hodgkin Lymphoma (NHL)|Juvenile Myelomonocytic Leukemia (JMML)|Chronic Myeloid Leukemia (CML) | 2019-01-31 | PHASE2 |
| NCT07199855 | Zhejiang University | B-Cell Acute Lymphoblastic Leukemia, Adult | 2025-06-01 | PHASE2 |
| NCT07178912 | M.D. Anderson Cancer Center|Amgen|Ascentage Pharma Group Inc. | Phase II Clinical Trial|Blinatumomab|Olverembatinib|Lymphoblastic Leukemia|Philadelphia Chromosome Positive | 2026-08-27 | PHASE2 |
| NCT04448834 | Dorothy Sipkins, MD, PhD|Amgen|Acrotech Biopharma Inc. | B-cell Acute Lymphoblastic Leukemia | 2022-01 | PHASE2 |
| NCT00560794 | Amgen Research (Munich) GmbH | Acute Lymphoblastic Leukemia | 2008-01 | PHASE2 |
| NCT05519579 | Northside Hospital, Inc. | Acute Lymphoblastic Leukemia | 2023-06-30 | PHASE2 |
| NCT00274742 | Amgen Research (Munich) GmbH | Non-Hodgkin´s Lymphoma, Relapsed | 2004-06 | PHASE1 |
| NCT05327894 | Princess Maxima Center for Pediatric Oncology|University of Milano Bicocca|Amgen Europe B.V | Acute Lymphoblastic Leukemia|Mixed Phenotype Acute Leukemia | 2022-12-15 | PHASE3 |
| NCT03931642 | French Innovative Leukemia Organisation|Amgen | Richter Syndrome | 2019-07-05 | PHASE2 |
| NCT06075238 | Sichuan University | Leukemia, Lymphoid | 2023-10-01 | PHASE2 |
| NCT04307576 | Mats Heyman|The Swedish Research Council|The Swedish Childhood Cancer Foundation|Pfizer|Servier|NordForsk|Aamu Pediatric Cancer Foundation|German Society for Pediatric Oncology and Hematology GPOH gGmbH|Clinical Trial Center North (CTC North GmbH & Co. KG)|Belgium Health Care Knowledge Centre|Karolinska Institutet|Cancer Research UK|Funda??o Rui Osório de Castro|Acreditar - Associa??o de Pais e Amigos das Crian?as com Cancro|Grupo Português De Leucemias Pediátricas|Amgen|Nova Laboratories Limited|Danish Child Cancer Foundation|Danish Cancer Society|The Novo Nordic Foundation|Assistance Publique - H?pitaux de Paris|Direction Générale de l´Offre de Soins|Swedish Cancer Society | Leukemia, Acute Lymphoblastic | 2020-07-13 | PHASE3 |
| NCT03476239 | Amgen | Acute Lymphoblastic Leukemia | 2017-10-18 | PHASE3 |
| NCT07227584 | Dana-Farber Cancer Institute | Acute Lymphoblastic Leukemia|Philadelphia Chromosome-Negative Lymphoblastic Leukemia|Acute Lymphoblastic Leukemia (ALL)|Leukemia | 2026-04 | PHASE2 |
| NCT01207388 | Amgen Research (Munich) GmbH | B-cell Acute Lymphoblastic Leukemia | 2010-11 | PHASE2 |
| NCT06882057 | Institute of Hematology & Blood Diseases Hospital, China | Acute Lymphoblastic Leukemia ALL|Childhood Leukemia, Acute Lymphoblastic|B Cell Acute Lymphoblastic Leukemia (B-ALL) | 2025-03-03 | PHASE2|PHASE3 |
| NCT04604691 | Seoul National University Hospital|Amgen | Pediatric ALL, B Cell|Minimal Residual Disease | 2022-02-18 | PHASE1 |
| NCT03751709 | Cedars-Sinai Medical Center|Amgen | B-Cell Acute Lymphoblastic Leukaemia|ALL, Adult|B-ALL | 2020-02-14 | PHASE1 |
| NCT06237192 | National Research Center for Hematology, Russia | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2023-04-01 | NA |
| NCT02003222 | National Cancer Institute (NCI)|Canadian Cancer Trials Group | Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | 2014-05-19 | PHASE3 |
| NCT07495631 | Institute of Hematology & Blood Diseases Hospital, China | Acute Lymphoblastic Leukemia, Adult | 2026-03-01 | NA |
| NCT02807883 | M.D. Anderson Cancer Center|Amgen | Acute Lymphoblastic Leukemia | 2016-08 | PHASE2 |
| NCT04827745 | University of Maryland, Baltimore | Mixed Phenotype Acute Leukemia (MPAL)|Measurable Residual Disease (MRD) | 2021-06-11 | PHASE2 |
| NCT04260022 | Ascentage Pharma Group Inc. | Leukemia, Myeloid, Chronic|Myeloid Leukemia|Chronic Myeloid Leukemia|Philadelphia Positive Acute Lymphoblastic Leukemia|B Cell Precursor Type Acute Leukemia | 2020-01-09 | PHASE1 |
| NCT04746209 | Medical College of Wisconsin|Amgen|University of Wisconsin, Madison | B-cell Acute Lymphoblastic Leukemia|B-cell Childhood Acute Lymphoblastic Leukemia|B-Cell ALL, Childhood | 2021-02-01 | PHASE2 |
| NCT02013167 | Amgen | Relapsed+Refractory B-precursor Acute Lymphoblastic Leukemia | 2014-01-03 | PHASE3 |
| NCT04785547 | Prof. Christina Peters|Amgen | ALL, Childhood|Minimal Residual Disease | 2020-12-17 | PHASE2 |
| NCT06658938 | Institute of Hematology & Blood Diseases Hospital, China | B-ALL | 2024-11-01 | NA |
| NCT07387926 | Novartis Pharmaceuticals | Acute Lymphoblastic Leukemia|Leukemia, Lymphoblastic, Acute, Philadelphia-Positive|Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | 2026-03-26 | PHASE1|PHASE2 |
| NCT04530565 | National Cancer Institute (NCI) | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | 2021-01-25 | PHASE3 |
| NCT02790515 | St. Jude Children´s Research Hospital | Acute Lymphoblastic Leukemia (ALL)|Acute Myeloid Leukemia (AML)|Myeloid Sarcoma|Chronic Myeloid Leukemia (CML)|Juvenile Myelomonocytic Leukemia (JMML)|Myelodysplastic Syndrome (MDS)|Non-Hodgkin Lymphoma (NHL) | 2016-07-14 | PHASE2 |
| NCT04556084 | Michael Burke|Amgen | B-cell Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia|Relapsed B-cell Acute Lymphoblastic Leukemia | 2021-01-01 | PHASE2 |
| NCT07297914 | Bambino Gesù Hospital and Research Institute | Acute Lymphoblastic Leukemia (ALL)|Stem Cell Transplant|Graft -Versus-host-disease | 2026-01-15 | PHASE2|PHASE3 |
| NCT05557110 | Chen Suning | B Acute Lymphoblastic Leukemia | 2022-09-08 | PHASE2 |
| NCT02910063 | Amgen | B-Cell Non Hodgkin Lymphoma | 2017-01-23 | PHASE2|PHASE3 |
| NCT06061094 | Goethe University|Deutsche Leuk?mie- & Lymphom-Hilfe|German Federal Ministry of Education and Research | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | 2023-07-14 | PHASE2 |
| NCT01466179 | Amgen Research (Munich) GmbH | Acute Lymphoblastic Leukemia | 2011-12 | PHASE2 |
| NCT07573670 | The First Affiliated Hospital of Soochow University | Newly Diagnosed Mixed Phenotype Acute Leukemia | 2026-05-01 | PHASE2 |
| NCT07134088 | Amgen|BeOne Medicines | Relapsed+Refractory B-Cell Precursor Acute Lymphoblastic Leukemia|Minimal Residual Disease &addition; B-Cell Acute Lymphoblastic Leukemia | 2025-12-08 | PHASE1|PHASE2 |
| NCT03512405 | City of Hope Medical Center|National Cancer Institute (NCI) | CD19 Positive|Philadelphia Chromosome Positive|Recurrent Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia | 2019-08-02 | PHASE1|PHASE2 |
| NCT06649422 | Shandong University|Shandong Provincial Hospital|The Affiliated Hospital of Qingdao University|Tangshan Central Hospital|Affiliated Central Hospital of Shandong First Medical University|Yantai Yuhuangding Hospital|Qilu Hospital of Shandong University (Qingdao)|Qingdao Central Hospital|Qingdao Municipal Hospital|Affiliated Hospital of Jining Medical University|Affiliated Hospital of Binzhou Medical College|Linyi People´s Hospital|The Second Hospital of Shandong University|Affiliated Hospital of Shandong University of Traditional Chinese Medicine|Shandong First Medical University|Shengli Oilfield Hospital|Heze Municipal Hospital|Zibo Central Hospital|Zaozhuang Municipal Hospital|Weihai Municipal Hospital | Leukemia, Lymphocytic, Acute, Adult | 2024-11-01 | |
| NCT03263572 | M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Amgen|Takeda | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Lymphoblastic Leukemia|BCR-ABL1 Fusion Protein Expression|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Philadelphia Chromosome Positive|Recurrent Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia|t(9;22) | 2017-11-29 | PHASE2 |
| NCT06317662 | National Cancer Institute (NCI) | Acute Leukemia of Ambiguous Lineage|B Acute Lymphoblastic Leukemia | 2025-06-05 | PHASE2 |
| NCT02000427 | Amgen | Relapsed+Refractory Philadelphia Positive B-precursor ALL | 2014-01-03 | PHASE2 |
| NCT07153796 | M.D. Anderson Cancer Center|Amgen | B-cell Acute Lymphoblastic Leukemia | 2026-01-30 | PHASE2 |
| NCT06570798 | Amgen | Systemic Lupus Erythematosus|Active Refractory Rheumatoid Arthritis | 2025-07-16 | PHASE2 |
| NCT06742515 | First Affiliated Hospital of Zhejiang University | Precursor B-Cell Acute Lymphoblastic Leukemia | 2024-10-17 | PHASE2 |
| NCT06991920 | Institute of Hematology & Blood Diseases Hospital, China | Adult ALL|MPAL | 2026-06-30 | NA |
| NCT05192889 | St. Jude Children´s Research Hospital|AbbVie | Refractory Acute Lymphoblastic Leukemia|Relapsed Acute Lymphoblastic Leukemia | 2022-08-25 | PHASE1|PHASE2 |
| NCT03605589 | Children´s Hospital Medical Center, Cincinnati | Leukemia, B-cell|Lymphoma, B-Cell | 2018-09-27 | PHASE1 |
| NCT06886074 | Hospital Universitario Dr. Jose E. Gonzalez | Acute Lymphoblastic Leukemia|Measurable Residual Disease (MRD) | 2025-01-02 | PHASE2 |
| NCT03739814 | National Cancer Institute (NCI) | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative|Recurrent B Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia | 2019-05-08 | PHASE2 |
| NCT06860269 | Assistance Publique - H?pitaux de Paris | Acute Lymphoblastic Leukemia | 2025-05-06 | PHASE2|PHASE3 |
| NCT03709719 | Assistance Publique - H?pitaux de Paris | Acute Lymphoblastic Leukemia, Adult B-Cell | 2018-10-20 | PHASE2 |
| NCT03982992 | Ludwig-Maximilians - University of Munich|Amgen | B Cell Precursor Acute Lymphoblastic Leukemia With Mixed Chimerism or Minimal Residual Disease After Allogeneic Stem Cell Transplantation|B-Cell Acute Lymphoblastic Leukemia|Acute Lymphoblastic Leukemia|Acute Lymphoblastic Leukemia in Remission|Acute Lymphoblastic Leukemia, Adult | 2019-06-01 | PHASE2 |
| NCT03367299 | Gruppo Italiano Malattie EMatologiche dell´Adulto | Acute Lymphoid Leukemia|Philadelphia Chromosome-Negative B-Cell Precursor | 2018-06-08 | PHASE2 |
| NCT07476729 | Charite University, Berlin, Germany | B-Cell Acute Lymphoblastic Leukaemia | 2026-04-01 | PHASE3 |
| NCT06607991 | The Children´s Hospital of Zhejiang University School of Medicine | CNI-resistant Steriod Resistant Nephrotic Syndrome|CNI-intolerent|Steriod Resistant Nephrotic Syndrome|Multidrug Resistant Nephrotic Syndrome | 2024-09-19 | PHASE1 |
| NCT06764238 | Institute of Hematology & Blood Diseases Hospital, China | Acute Lymphoblastic Leukemia ALL|Childhood Leukemia, Acute Lymphoblastic|B Cell Acute Lymphoblastic Leukemia (B-ALL) | 2025-01-03 | PHASE2|PHASE3 |
| NCT03480438 | Goethe University | B-Precursor ALL | 2018-06-01 | PHASE2 |
| NCT03023878 | Amgen | High-risk Diffuse Large B-Cell Lymphoma | 2017-03-13 | PHASE2 |
| NCT02393859 | Amgen | Leukemia, Acute Lymphoblastic | 2015-11-10 | PHASE3 |
| NCT07222579 | West Virginia University|Amgen | CD19 Positive|Mixed Phenotype Acute Leukemia (MPAL) | 2026-01-15 | PHASE2 |
| NCT04723342 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Childhood Acute Lymphoblastic Leukemia | 2020-02-01 | NA |
| NCT02997761 | University of California, Davis|National Cancer Institute (NCI)|Pharmacyclics LLC. | Adult B Acute Lymphoblastic Leukemia|Philadelphia Chromosome Positive | 2017-06-27 | PHASE2 |
| NCT04506086 | Amgen | B-precursor Acute Lymphoblastic Leukemia | 2021-08-26 | PHASE4 |
| NCT03318770 | Gruppo Italiano Malattie EMatologiche dell´Adulto | Acute Lymphoblastic Leukemia | 2019-05-10 | |
| NCT06075212 | Sichuan University | Leukemia, Lymphoid | 2023-10-01 | |
| NCT04688983 | Cardiff University | Acute Lymphoblastic Leukemia, Adult | 2021-01 | PHASE2 |
| NCT03160079 | University of California, San Diego|Merck Sharp & Dohme LLC|Amgen | B-Cell Acute Lymphoblastic Leukemia, Adult | 2017-08-04 | PHASE1|PHASE2 |
| NCT06308588 | M.D. Anderson Cancer Center|Novartis Pharmaceuticals | Philadelphia Chromosome-Positive|Acute Lymphoblastic Leukemia | 2024-08-05 | PHASE1|PHASE2 |
| NCT04722848 | Gruppo Italiano Malattie EMatologiche dell´Adulto | Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)|ALL, Adult|Philadelphia-Positive ALL | 2021-09-08 | PHASE3 |
| NCT07301424 | University of Alberta|Amgen | Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph&addition;)|BCR-ABL Positive Acute Lymphoblastic Leukemia | 2026-07-01 | PHASE2 |
| NCT01209286 | Amgen Research (Munich) GmbH | B-ALL | 2010-10 | PHASE2 |
| NCT06438796 | Ruijin Hospital | High Risk Acute Lymphoblastic Leukemia | 2024-07-01 | PHASE2 |
| NCT04334993 | Israeli Medical Association | Philadelphia-Negative ALL|High-Risk Cancer | 2021-01-01 | PHASE2 |
| NCT05848687 | Tanja Andrea Gruber|The Pediatric Oncology Experimental Therapeutics Investigators´ Consortium|Amgen|Lucile Packard Foundation for Children´s Health|Kura Oncology, Inc.|United States Department of Defense|Cannonball Kid´s Cancer | Lymphoblastic Leukemia | 2023-11-03 | PHASE1|PHASE2 |
| NCT06393985 | The First Affiliated Hospital of Soochow University | B-cell Acute Lymphoblastic Leukemia | 2024-04-25 | PHASE2 |
| NCT05559450 | The First Affiliated Hospital of Soochow University|Fujian Medical University Union Hospital|Zhongda Hospital|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|The First People´s Hospital of Changzhou|Wuxi People´s Hospital|First Affiliated Hospital of Wannan Medical College | B-cell Acute Lymphoblastic Leukemia | 2022-02-01 | PHASE2 |
| NCT06985485 | The First Affiliated Hospital of Soochow University | Acute Lymphoblastic Leukemia|Immunotherapy|Blinatumomab|Inotuzumab Ozogamicin | 2025-05-17 | PHASE2 |
| NCT07003737 | First Affiliated Hospital of Zhejiang University | Acute Lymphoblastic Leukemia, B-precursor | 2025-02-05 | NA |
| NCT06930105 | Xianmin Song, MD | Acute Lymphoid Leukemia (ALL) | 2025-09-01 | PHASE2 |
| NCT03121534 | M.D. Anderson Cancer Center|Amgen | Hematopoietic+Lymphoid Cancer|Richter´s Transformation | 2017-06-22 | PHASE2 |
| NCT04546399 | National Cancer Institute (NCI) | Down Syndrome|Recurrent B Acute Lymphoblastic Leukemia | 2020-12-17 | PHASE2 |
| NCT05645718 | M.D. Anderson Cancer Center | Leukemia | 2023-07-14 | PHASE2 |
| NCT03959085 | Children´s Oncology Group|National Cancer Institute (NCI) | B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma|Central Nervous System Leukemia|Mixed Phenotype Acute Leukemia|Testicular Leukemia | 2019-10-31 | PHASE3 |
| NCT02879695 | National Cancer Institute (NCI) | Recurrent B Acute Lymphoblastic Leukemia|Recurrent Mixed Phenotype Acute Leukemia|Refractory B Acute Lymphoblastic Leukemia|Refractory Mixed Phenotype Acute Leukemia | 2017-10-25 | PHASE1 |
| NCT03114865 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Amgen | Acute Lymphoblastic Leukemia|B-cell Non Hodgkin Lymphoma|Pre B-Cell Acute Lymphoblastic Leukaemia | 2017-09-05 | PHASE1|PHASE2 |
| NCT01371630 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative|Burkitt-Like Lymphoma With 11q Aberration|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements|High Grade B-Cell Lymphoma, Not Otherwise Specified|Recurrent B Acute Lymphoblastic Leukemia|Recurrent Burkitt Lymphoma|Refractory B Acute Lymphoblastic Leukemia|Refractory Burkitt Lymphoma | 2011-08-26 | PHASE1|PHASE2 |
| NCT02811679 | Massachusetts General Hospital|Amgen | Non-Hodgkin Lymphoma | 2016-08 | PHASE2 |
| NCT06789107 | Mao Jianhua | Systemic Lupus Erythematosus (SLE)|Children|Blinatumomab | 2024-12-08 | PHASE1 |
| NCT03523429 | PETHEMA Foundation | Philadelphia Chromosome-negative or BCR-ABL-negative, CD19-positive ALL | 2018-06-30 | PHASE2 |
| NCT06836973 | Da, Yuwei, M.D. | Myasthenia Gravis | 2025-04-01 | PHASE2|PHASE3 |
| NCT06124157 | National Cancer Institute (NCI) | B Acute Lymphoblastic Leukemia | 2025-05-30 | PHASE2 |
| NCT06125106 | Zhejiang University | Acute Lymphoblastic Leukemia | 2023-11-16 | PHASE1 |
| NCT00538096 | MedImmune LLC | Lymphoma, B-Cell|Lymphoma, Non-Hodgkin | 2007-09 | PHASE1 |
| NCT00676871 | MedImmune LLC | Chronic Lymphocytic Leukemia | 2008-06 | PHASE1|PHASE2 |